Private payers are gradually adopting genomic testing to guide decision making in treatment pathways for selected disorders. There is still some uncertainty regarding the future uptake of genomic testing and the levels of sophistication of new tests, and this article discusses some relevant considerations that can support a greater appreciation of the risks and gains to payers involved in funding these tests now.

This article was originally published in the February 2018 issue of Health Watch.